Edgar Filing: Scheer David - Form 4

Scheer Day	vid								
Form 4 December	14 2011								
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						PPROVAL 3235-0287			
	this box			Simgton	, D.C. 2	004)		Expires:	January 31,
if no lo subject Sectior Form 4 Form 5 obligat may co	to 16. or ions ions section 17(rsuant to S (a) of the F	F CHANGES IN BENEFICIAL OWNERSE SECURITIES Section 16(a) of the Securities Exchange Act o Public Utility Holding Company Act of 1935 of				nge Act of 1934, of 1935 or Secti	Estimated burden hou response	urs per
<i>See</i> Ins 1(b).	truction	30(n)	of the f	nvestment	. Compa	ny Act of 1	1940		
(Print or Type	e Responses)								
1. Name and Address of Reporting Person * Scheer David (Last) (First) (Middle) C/O ACHILLION PHARMACEUTICALS, 300 GEORGE STREET			2. Issuer Name and Ticker or Trading Symbol ACHILLION PHARMACEUTICALS INC [ACHN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			3. Date of Earliest Transaction (Month/Day/Year) 12/12/2011				X_ Director Officer (give below)		· • •
(Street) NEW HAVEN, CT 06511			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tał	ole I - Non-l	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if		nAcquired Disposed (Instr. 3,	(A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect
Reminder: R	eport on a separate line	e for each cla	ass of sec	urities bene	-	-	-		
					inforı requi	mation con red to resp	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

Edgar Filing: Scheer David - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 7.59	12/12/2011		А	20,000	<u>(1)</u>	12/12/2021	Common Stock	20,000	
Reporting Owners										
				Relation	ships					

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Scheer David C/O ACHILLION PHARMACEUTICALS 300 GEORGE STREET NEW HAVEN, CT 06511	Х						
Signatures							
/s/ Mary Kay Fenton, Attorney-in-fact for D Scheer	12/14/2011						
**Signature of Reporting Person		1	Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option grant vests as to 25% on the date of grant and as to an additional 2.08% at the end of each monthly period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S ()